<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00658749</url>
  </required_header>
  <id_info>
    <org_study_id>AIR645-CS1</org_study_id>
    <nct_id>NCT00658749</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma</brief_title>
  <acronym>AIR645-CS1</acronym>
  <official_title>A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altair Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altair Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase one study to evaluate the safety, tolerability, and bioavailability of
      nebulized AIR645.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measures of the safety and tolerability of AIR645 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, pulmonary function tests, heart rhythm, and laboratory tests.</measure>
    <time_frame>During dosing and for two weeks after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>During dosing and for two weeks after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiologic saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIR645</intervention_name>
    <description>AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiologic saline solution</intervention_name>
    <description>Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria*:

          -  Good General Health (with or without allergic rhinitis and/or controlled asthma)

          -  Non-smoker for at least 2 years

          -  Normal lung function (DLCO)

          -  Able to provide informed consent and to understand and comply with the requirements of
             the study

        Exclusion Criteria*:

          -  Clinically significant medical history or condition which precludes participation

          -  Clinically significant ECG abnormality

          -  Clinically significant VS or PE abnormality

          -  Clinically significant screening lab abnormality

          -  Abnormal lung function (FEV1 &lt;80% predicted)

          -  Respiratory infection within 14 days of randomization

          -  HBV, HCV, or HIV

          -  Breastfeeding or pregnant female

          -  History of alcohol abuse or illicit drug use within past 24 months

          -  Use of any tobacco or nicotine-containing product within past 6 months

          -  Use of any herbal supplement, over-the-counter drug, or prescription drug that is not
             allowed per protocol

          -  Use of any investigational drug within past 30 days

          -  Use of any investigational monoclonal antibody or recombinant protein within past 90
             days

          -  Donation of plasma within past 7 days

          -  Donation or loss of whole blood within past 56 days

               -  Simplified list of I/E criteria; unabridged list available upon request.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Hodges, MD</last_name>
    <role>Study Director</role>
    <affiliation>Altair Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contract Research Organization (CRO) appointed by Altair Therapeutics--Altair's offices are in:</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2008</study_first_submitted>
  <study_first_submitted_qc>April 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2008</study_first_posted>
  <last_update_submitted>June 24, 2009</last_update_submitted>
  <last_update_submitted_qc>June 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Susan Gregory/Chief Scentific Officer</name_title>
    <organization>Altair Therapeutics, Inc.</organization>
  </responsible_party>
  <keyword>AIR645</keyword>
  <keyword>Altair Therapeutics</keyword>
  <keyword>IL4</keyword>
  <keyword>IL13</keyword>
  <keyword>IL-4</keyword>
  <keyword>IL-13</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

